International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-5 doi: 10.5281/zenodo.8388203
Original Article
Is Adaptive Support Ventilation Superior Over Assist/Control Mode Ventilation in Critically Ill Patients?
 ,
Published
Sept. 28, 2023
Abstract

Background: ASV is adaptive mode of ventilation where a target ventilator pattern is automatically chosen. This study was undertaken to compare the clinical parameters between ASV and ACMV mode of ventilation.

Material and Methods: A prospective study was undertaken in 60 critically ill patients who were randomly divided in to two equal groups i.e., ASV and ACMV modes of mechanical ventilation. Group A patients were ventilated by using ASV mode of ventilation and 30 patients of Group B were ventilated by using ACMV mode of ventilation. The patients particulars including number of days of ventilation, number of days of in ICU and number deaths were entered. APACHE and SOFA scores were calculated and compared.

Results: About 40.0% of the cases in ACMV group and 33.3% in ASV group were aged more than 60 years. Males were higher in ACMV group and females in ASV group. Mean number of days of ventilation in ACMV group was 6.8 days in ASV group was 5.53 days. Mean number of days of stay in ICU was 9.53 days in ACMV group and 8.53 days in ASV group which was statistically significant. About 10.0% of the cases in ACMV group and 6.7% of the cases in ASV group died during follow up. Mean APACHE score was 22.13 in ACMV group and 18.0 in ASV group and it was statistically significant between the two groups. SOFA score was 5.8 ACMV group and 4.57 in ASV group which was statistically significant.

Conclusion: This study concludes that, ASV mode of ventilation in reduction of ICU stay, duration of ventilation, low APACHE & SOFA scores.

Recommended Articles
Loading Image...
Volume-4, Issue-5
Citations
1119 Views
388 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved